IQ-AI Ltd

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI RNS News & Announcements
  • IB Stroke
 

News

Thursday, 15 October 2020 / Published in IQ-AI RNS News & Announcements

IB Stroke

RNS Number : 1272C
IQ-AI Limited
15 October 2020
 

 

15 October 2020

 

IQ-AI Ltd

(“IQ-AI” or the “Company”)

 

IB Stroke™

 

IQ-AI, Ltd is pleased to announce the launch of IB Stroke, marking the completion of a key new product introduction that further increases IQ-AI’s footprint in neuro imaging. IB Stroke is immediately available as a set of workflows processed by the highly flexible and customizable IB Rad Tech platform. It provides users with the flexibility to process both MR and CT perfusion image sets, thus allowing use in any imaging environment. The IB Stroke output may be used by clinicians to help determine the usefulness of treating the patient with clot-busting drugs – drugs which can potentially save oxygen-starved brain tissue but bring with them a host of potential side-effects.  

 

In the USA alone, approximately 800,000 people experience a stroke each year and stroke remains a leading cause of disability. Current annual stroke related costs are $46 billion and are projected to increase to $94 billion by 2035. By capitalizing on existing software capabilities and regulatory clearances of the IB Clinic® software suite, IB Stroke is available in both Europe (CE Marked) and the US (FDA-cleared) markets. IQ-AI intends to serve this sizable market through annual subscriptions to IB Stroke.

 

“The development team at IB met a very aggressive timeline and delivered on providing an extremely efficient and foundational software solution for stroke assessment,” said Trevor Brown, IQ-AI’s CEO. “With the on-schedule completion of IB Stroke, resources will now shift to the development of IB Trax™ which will also leverage core IB algorithms including Delta T1 maps”.

 

IB recently submitted an application to the US Patent and Trademark Office for their Delta T1 mapping process. Delta T1 maps are a foundational in the assessment of brain images that use a contrast agent.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

 

-ENDS-

For further information, please contact:

 

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at   www.imagingbiometrics.com.

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source

Recent Posts

  • Notice of AGM

    RNS Number : 4440K IQ-AI Limited 05 May 2022   ...
  • IB Broadens Quantitative Mapping

    RNS Number : 1476K IQ-AI Limited 03 May 2022   ...
  • IB Broadens Quantitative Mapping

    – Article source...
  • Final Results

    RNS Number : 7683J IQ-AI Limited 28 April 2022 ...
  • IQAI’s Sponsored Phase I Clinical Trial is Open

    RNS Number : 2319E IQ-AI Limited 09 March 2022 ...
Portions copyright © 2010-2022 IQ-AI Ltd. All Rights Reserved.
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT